Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs.

Clin Transl Med · 2018 · PMC5852245 · PMID 29541939

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

almost insignificantno p-value reported

For example, reports for trials that use combination of gemcitabine plus carboplatin, showed outcomes of progression-free survival of only 3.6 months reported for control arm (almost insignificant, and no cure).

also in 529 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.